Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Abstract

Brentuximab vedotin is an antibody drug conjugate that induces durable objective responses in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Fifteen of 160 patients who participated in two pivotal phase 2 studies received a consolidative allogeneic stem cell transplant (allo-SCT) following brentuximab vedotin treatment. This case series describes their experience. The studies were approved by Institutional Review Boards prior to patient enrollment. Patients received 1.8 mg/kg brentuximab vedotin every 3 weeks for up to 16 cycles. The estimated 2-year progression-free survival (PFS) rate was 66%, and the median PFS has not yet been reached. Eleven of the 15 patients were alive and the estimated 2-year survival rate was 80%. The safety of brentuximab vedotin treatment in this series was consistent with the known safety profile in this setting. Brentuximab vedotin is a compelling option for reducing tumor burden to facilitate a consolidative allo-SCT.

Keywords::

• Lymphoma and Hodgkin disease
• antibody-based immunotherapy
• immunotherapeutic approaches
• marrow and stem cell transplant

Acknowledgements

The authors would like to thank Liz Thomas for statistical guidance under the sponsorship of Seattle Genetics, Inc. Medical writing assistance was provided by Eilidh Williamson under the sponsorship of Seattle Genetics, Inc. We acknowledge Joseph D. Rosenblatt, MD, for recruiting patients into the studies. R.C. was supported by the National Cancer Institute of the National Institutes of Health under award number K12CA001727. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Direct funding for this research was issued by Seattle Genetics, Inc. through the joint financial support of Seattle Genetics, Inc. and Takeda Pharmaceuticals International Company.